Prostate Cancer Clinical Trial
PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
Summary
The goal of this clinical trial is to evaluate the safety of the AQUABEAM Robotic System in treating patients with localized prostate cancer. Participants will go through baseline and follow up assessments up to 12 months.
Eligibility Criteria
Inclusion Criteria:
Clinical Stage ≤ T2c
PSA ≤ 20 ng/ml
Prostate volume ≥ 30 ml
Grade Group (GG) 1 or 2: If GG 1: ≥ 3 cores positive for cancer. Note, multiple positive from any MRI targeted lesion will be considered as a single positive core.
Exclusion Criteria:
Any prior or current treatment for prostate cancer, including but not limited to surgery, radiation therapy (external or brachytherapy), tissue ablation or chemotherapy.
Patients with previous surgical or minimally invasive treatment of benign prostatic hyperplasia within the prior 12 months.
Radiographically suspicious lymph node involvement confirmed with biopsy or PET scan.
Evidence of bone metastasis.
Evidence of extracapsular involvement.
Evidence of seminal vesicle invasion on DRE or MRI read as "definite", "probable" or "consistent with"
Any condition or history of illness or surgery that may pose an additional risk to men undergoing the Aquablation procedure.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Los Angeles California, 90033, United States More Info
How clear is this clinincal trial information?
